1-(1,3-Dichloroisoquinolin-5-yl)sulfonylazetidine-3-carboxylic acid | 1392443-28-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: 1-(1,3-Dichloroisoquinolin-5-yl)sulfonylazetidine-3-carboxylic acid
• CAS: 1392443-28-5
• 化学式: C₁₃H₁₀Cl₂N₂O₄S
• 分子量: 361.205
• InChiKey: GKYPAHOMXIEJBX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  96
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1-(1,3-Dichloroisoquinolin-5-yl)sulfonylazetidine-3-carboxylic acid 、 1-(4-吡啶基)哌嗪 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 [1-(1,3-Dichloroisoquinolin-5-yl)sulfonylazetidin-3-yl]-(4-pyridin-4-ylpiperazin-1-yl)methanone
  参考文献：
  名称：

  Development of novel M1 antagonist scaffolds through the continued optimization of the MLPCN probe ML012

  摘要：

  This Paper describes the continued optimization of an MLPCN probe molecule M-1 antagonist (ML012) through an iterative parallel synthesis approach. After several rounds of modifications of the parent compound, we arrived at a new azetidine scaffold that displayed improved potency while maintaining a desirable level of selectivity over other muscarinic receptor subtypes. Data for representative molecules 7w (VU0452865) and 12a (VU0455691) are presented. (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.06.018
• 作为产物：
  描述：

  1,3-Dichloroisoquinoline-5-sulfonyl chloride 在 水 、 三乙胺 、 sodium hydroxide 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成 1-(1,3-Dichloroisoquinolin-5-yl)sulfonylazetidine-3-carboxylic acid
  参考文献：
  名称：

  Development of novel M1 antagonist scaffolds through the continued optimization of the MLPCN probe ML012

  摘要：

  This Paper describes the continued optimization of an MLPCN probe molecule M-1 antagonist (ML012) through an iterative parallel synthesis approach. After several rounds of modifications of the parent compound, we arrived at a new azetidine scaffold that displayed improved potency while maintaining a desirable level of selectivity over other muscarinic receptor subtypes. Data for representative molecules 7w (VU0452865) and 12a (VU0455691) are presented. (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.06.018

文献信息

• Development of novel M1 antagonist scaffolds through the continued optimization of the MLPCN probe ML012
  作者：Bruce J. Melancon、Thomas J. Utley、Christian Sevel、Margrith E. Mattmann、Yiu-Yin Cheung、Thomas M. Bridges、Ryan D. Morrison、Douglas J. Sheffler、Colleen M. Niswender、J. Scott Daniels、P. Jeffrey Conn、Craig W. Lindsley、Michael R. Wood

  DOI：10.1016/j.bmcl.2012.06.018

  日期：2012.8

  This Paper describes the continued optimization of an MLPCN probe molecule M-1 antagonist (ML012) through an iterative parallel synthesis approach. After several rounds of modifications of the parent compound, we arrived at a new azetidine scaffold that displayed improved potency while maintaining a desirable level of selectivity over other muscarinic receptor subtypes. Data for representative molecules 7w (VU0452865) and 12a (VU0455691) are presented. (c) 2012 Elsevier Ltd. All rights reserved.